DE60112611D1 - Makroheterocyclische verbindungen als kinase inhibitoren - Google Patents

Makroheterocyclische verbindungen als kinase inhibitoren

Info

Publication number
DE60112611D1
DE60112611D1 DE60112611T DE60112611T DE60112611D1 DE 60112611 D1 DE60112611 D1 DE 60112611D1 DE 60112611 T DE60112611 T DE 60112611T DE 60112611 T DE60112611 T DE 60112611T DE 60112611 D1 DE60112611 D1 DE 60112611D1
Authority
DE
Germany
Prior art keywords
kinase inhibitors
kinase
compounds
macroheterocyclic compounds
macroheterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60112611T
Other languages
English (en)
Other versions
DE60112611T2 (de
Inventor
Gee-Hong Kuo
Catherine Prouty
Alan Deangelis
Han-Cheng Zhang
Peter Conolly
William V Murray
R Shah
Bruce E Maryanoff
B White
Lan Shen
Bruce Conway
Keith Demarest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Application granted granted Critical
Publication of DE60112611D1 publication Critical patent/DE60112611D1/de
Publication of DE60112611T2 publication Critical patent/DE60112611T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
DE60112611T 2000-12-08 2001-12-06 Makroheterocyclische verbindungen als kinase inhibitoren Expired - Lifetime DE60112611T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25416100P 2000-12-08 2000-12-08
PCT/US2001/047866 WO2002046197A1 (en) 2000-12-08 2001-12-06 Macroheterocylic compounds useful as kinase inhibitors

Publications (2)

Publication Number Publication Date
DE60112611D1 true DE60112611D1 (de) 2005-09-15
DE60112611T2 DE60112611T2 (de) 2006-06-14

Family

ID=22963161

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60112611T Expired - Lifetime DE60112611T2 (de) 2000-12-08 2001-12-06 Makroheterocyclische verbindungen als kinase inhibitoren

Country Status (12)

Country Link
US (1) US6828327B2 (de)
EP (1) EP1345946B1 (de)
JP (1) JP2004526676A (de)
AT (1) ATE301661T1 (de)
AU (2) AU2002227371B2 (de)
CA (1) CA2431187A1 (de)
DE (1) DE60112611T2 (de)
ES (1) ES2245994T3 (de)
HK (1) HK1055956A1 (de)
MX (1) MXPA03005139A (de)
RU (1) RU2275373C2 (de)
WO (1) WO2002046197A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346070T1 (de) 2002-03-05 2006-12-15 Lilly Co Eli Purinderivate als kinaseinhibitoren
AU2003217596A1 (en) 2002-03-08 2003-09-22 Eli Lilly And Company Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors
AU2003225295A1 (en) * 2002-05-08 2003-11-11 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
US20070282016A1 (en) * 2004-09-17 2007-12-06 Jenrow Kenneth A Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
PL1888123T3 (pl) 2005-06-08 2013-06-28 Janssen Biotech Inc Terapia komórkowa chorób degeneracyjnych oka
JP2009510085A (ja) * 2005-09-29 2009-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼインヒビターとしての大型複素環式化合物
EP1998776A4 (de) * 2006-03-10 2009-07-08 Janssen Pharmaceutica Nv Pyridinhaltige makroheterocyclische verbindungen als kinasehemmer
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
AU2007336338A1 (en) 2006-12-19 2008-06-26 Novartis Ag Indolylmaleimide derivatives as kinase inhibitors
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
KR101617243B1 (ko) 2007-07-31 2016-05-02 라이프스캔, 인코포레이티드 인간 배아 줄기 세포의 분화
MX2010005805A (es) 2007-11-27 2010-06-09 Lifescan Inc Diferenciacion de celulas madre embrionarias humanas.
CN101910177B (zh) 2007-12-24 2013-08-28 泰博特克药品公司 作为丙型肝炎病毒抑制剂的大环吲哚
JP5733986B2 (ja) 2008-02-21 2015-06-10 ヤンセン バイオテツク，インコーポレーテツド 細胞の付着、培養、及び剥離のための方法、表面改質されたプレート、並びに組成物
US8623648B2 (en) * 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
KR101651661B1 (ko) 2008-06-30 2016-08-26 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
CN102124012B (zh) * 2008-08-14 2014-07-02 泰博特克药品公司 可作为丙型肝炎病毒抑制剂的大环吲哚衍生物
US9012218B2 (en) 2008-10-31 2015-04-21 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
PL2346988T3 (pl) 2008-10-31 2017-10-31 Janssen Biotech Inc Różnicowanie ludzkich zarodkowych komórek macierzystych do linii endokrynnej trzustki
JP5719305B2 (ja) 2008-11-20 2015-05-13 ヤンセン バイオテツク，インコーポレーテツド 平面支持体上での細胞付着及び培養のための方法及び組成物
KR101774546B1 (ko) 2008-11-20 2017-09-04 얀센 바이오테크 인코포레이티드 마이크로-캐리어 상의 만능 줄기 세포 배양
EP2456858B1 (de) 2009-07-20 2018-08-29 Janssen Biotech, Inc. Differenzierung menschlicher embryonischer stammzellen
CN102482643B (zh) 2009-07-20 2016-06-29 詹森生物科技公司 人胚胎干细胞的分化
EP2456859A4 (de) 2009-07-20 2015-03-18 Janssen Biotech Inc Differenzierung menschlicher embryonischer stammzellen
EP2482837A4 (de) 2009-09-29 2013-05-22 Joslin Diabetes Center Inc Verwendung von proteinkinase-c-delta (pkcd-)hemmern zur behandlung von diabetes, adipositas und leberverfettung
CN102741395B (zh) 2009-12-23 2016-03-16 詹森生物科技公司 人胚胎干细胞的分化
EP2516626B1 (de) 2009-12-23 2017-05-10 Janssen Biotech, Inc. Differenzierung menschlicher embryonischer stammzellen
KR101831685B1 (ko) * 2010-01-25 2018-02-23 롬 앤드 하스 일렉트로닉 머트어리얼즈 엘엘씨 질소-함유 화합물을 포함하는 포토레지스트
EP2539709B1 (de) * 2010-02-22 2015-05-20 Blanchette Rockefeller Neurosciences, Institute Morbus-alzheimer-spezifische änderungen von proteinkinase-c-epsilon- (pkc-epsilon-)proteinspiegeln
JP6013196B2 (ja) 2010-03-01 2016-10-25 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞から誘導した細胞を精製するための方法
AU2011250912A1 (en) 2010-05-12 2012-11-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
AU2011296382B2 (en) 2010-08-31 2016-04-14 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2611907B1 (de) 2010-08-31 2016-05-04 Janssen Biotech, Inc. Differenzierung pluripotenter stammzellen
CA2809300A1 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2013033657A2 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY
SG10201608914WA (en) 2011-12-22 2016-12-29 Janssen Biotech Inc Differentiation of human embryonic stem cells into single hormonal insulin positive cells
KR20140131999A (ko) 2012-03-07 2014-11-14 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 증폭 및 유지를 위한 한정 배지
US10066210B2 (en) 2012-06-08 2018-09-04 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
BR112015015714A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
SG10201709338RA (en) 2012-12-31 2017-12-28 Janssen Biotech Inc Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
KR101942769B1 (ko) 2012-12-31 2019-01-28 얀센 바이오테크 인코포레이티드 Hb9 조절제를 사용하는 인간 배아 줄기세포의 췌장 내분비 세포로의 분화
CN117821369A (zh) 2014-05-16 2024-04-05 詹森生物科技公司 小分子增强胰腺内分泌细胞中的mafa表达的用途
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
BR112018001065A2 (pt) * 2015-07-21 2018-09-11 Tp Therapeutics, Inc. macrociclos diarila quirais e usos dos mesmos
RU2630958C2 (ru) * 2015-12-29 2017-09-15 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) Новые макроциклические соединения, содержащие природное 3,7-диазабицикло[3.3.1]нонановое ядро и способ их получения
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
KR102357045B1 (ko) 2017-03-31 2022-01-28 뉴로디아그노스틱스 엘엘씨 알츠하이머 질환에 대한 림프구-기반 형태계측 시험
US20200113979A1 (en) * 2017-06-12 2020-04-16 Temple University-Of The Commonwealth System Of Higher Education Protein Kinase C-delta targeted therapy for treating radiation injury
BR112020001695A2 (pt) 2017-07-28 2020-07-21 Turning Point Therapeutics, Inc. compostos macrocíclicos e usos dos mesmos
ES2929467T3 (es) 2017-12-19 2022-11-29 Turning Point Therapeutics Inc Compuestos macrocíclicos para tratar enfermedades
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007895A1 (en) * 1992-09-25 1994-04-14 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
YU49200B (sh) 1993-12-07 2004-09-03 Eli Lilly And Company Inhibitori proteinske kinaze c
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
EA001450B1 (ru) * 1996-05-01 2001-04-23 Эли Лилли Энд Компани Галогензамещенные ингибиторы протеинкиназы с
JP4405667B2 (ja) 1997-12-31 2010-01-27 セフアロン・インコーポレーテツド Ｋ−２５２ａの３’−エピマー誘導体
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
JP2004526676A (ja) 2004-09-02
AU2002227371B2 (en) 2007-05-10
DE60112611T2 (de) 2006-06-14
MXPA03005139A (es) 2004-01-29
ES2245994T3 (es) 2006-02-01
RU2275373C2 (ru) 2006-04-27
ATE301661T1 (de) 2005-08-15
EP1345946A1 (de) 2003-09-24
CA2431187A1 (en) 2002-06-13
HK1055956A1 (en) 2004-01-30
WO2002046197A1 (en) 2002-06-13
US20030078280A1 (en) 2003-04-24
US6828327B2 (en) 2004-12-07
EP1345946B1 (de) 2005-08-10
AU2737102A (en) 2002-06-18

Similar Documents

Publication Publication Date Title
ATE301661T1 (de) Makroheterocyclische verbindungen als kinase inhibitoren
DE60323749D1 (de) Substituierte pyrroline als kinase inhibitoren
ATE326464T1 (de) Indazolyl-substituierte pyrrolidin-verbindungen als kinase inhibitoren
DE60319364D1 (de) Substituierte pyrroline als kinase inhibitoren
CY1117951T1 (el) Αναστολεiς κινασης υποκατεστημενης τριαζινης
DK1355889T3 (da) Substituerede triazoldiaminderivater som kinaseinhibitorer
DE60222667D1 (de) Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
ES2153337T1 (es) Inhibidores de raf-quinasa.
HN2001000277A (es) PIRROLO [2,1 - a] DIHIDROISOQUINOLINAS
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
DE60329326D1 (de) Tace inhibitoren
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
AP2001002248A0 (en) Method for treating COPD.
SE0302361D0 (sv) Inhibering av upptagning av monoamin
CY1107287T1 (el) Χρηση της ερυθροποιητινης, καθως και παραγωγων αυτης για τη θεραπεια σχιζοφρενειων και συναφων ψυχωσεων
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN

8364 No opposition during term of opposition